NCT00389441 |
Axitinib |
Phase II, single arm |
Radioiodine-refractory thyroid cancer, regardless of histology |
52 |
Overall response rate |
Active, not recruiting |
NCT00510640 |
Sunitinib |
Phase II, single arm |
Thyroid cancer, regardless of histology |
66 |
Overall response rate |
Recruiting |
NCT00095836 |
Gefitinib |
Phase II, single arm |
Thyroid cancer, regardless of histology |
38 |
Overall response rate |
Active, not recruiting |
NCT01164176 |
Everolimus |
Phase II, single arm |
Thyroid cancer, regardless of histology |
32 |
Overall response rate |
Recruiting |
NCT01118065 |
Everolimus |
Phase II, single arm |
Thyroid cancer, regardless of histology |
42 |
Overall response rate |
Recruiting |
NCT00654238 |
Sorafenib |
Phase II, single arm |
Thyroid cancer, regardless of histology |
55 |
Overall response rate |
Recruiting |
NCT00625846 |
Pazopanib |
Phase II, single arm |
Thyroid cancer, regardless of histology |
188 |
Overall response rate |
Recruiting |
NCT01236547 |
Pazopanib |
Phase II, two arms |
Anaplastic thyroid cancer |
99 |
Overall response rate |
Recruiting |
Paclitaxel neoadjuvant, concomitant and adjuvant to radiotherapy with or without pazopanib |
NCT00126568 |
Sorafenib |
|
Anaplastic thyroid cancer |
36 |
Overall response rate |
Recruiting |
NCT00603941 |
CS7017 |
Phase I/ II |
Anaplastic thyroid cancer |
54 |
Maximum tolerated dose/Overall response rate |
Active, not recruiting |
NCT00115739 |
Imatinib |
Phase II |
Anaplastic thyroid cancer |
29 |
Overall response rate |
Active, not recruiting |